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Abstract
Background and Aims—Although the incidence of hepatocellular carcinoma (HCC) is
increasing in the United States, data from large prospective studies are limited. We evaluated the
hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) cohort for the incidence of
HCC and associated risk factors.
Methods—HCV-positive patients with bridging fibrosis or cirrhosis that did not respond to
peginterferon and ribavirin were randomized to groups that were given maintenance peginterferon
for 3.5 years or no treatment. HCC incidence was determined by Kaplan-Meier analysis and
baseline factors associated with HCC were analyzed by Cox regression.
Results—1,005 patients (mean age 50.2 years, 71% male, 72% white) were studied; 59% had
bridging fibrosis and 41% had cirrhosis. During a median follow-up of 4.6 years (maximum 6.7
years), HCC developed in 48 patients (4.8%). The cumulative 5-year HCC incidence was similar
for peginterferon-treated patients and controls, 5.4% vs. 5.0% (p=0.78), and was higher among
patients with cirrhosis than those with bridging fibrosis, 7.0% vs. 4.1% (p=0.08). HCC developed
in eight (17%) patients whose serial biopsies showed only fibrosis. A multivariate analysis model
comprising older age, black race, lower platelet count, higher alkaline phosphatase, esophageal
varices, and smoking was developed to predict the risk of HCC.
Conclusions—We found that maintenance peginterferon did not reduce the incidence of HCC
in the HALT-C cohort. Baseline clinical and laboratory features predicted risk for HCC.
Additional studies are required to confirm our finding of HCC in patients with chronic hepatitis C
and bridging fibrosis.
INTRODUCTION
Chronic hepatitis C is a potentially progressive condition, characterized by slowly evolving
fibrosis that can culminate in cirrhosis 1, 2. Over time, compensated cirrhosis can advance to
decompensated cirrhosis terminating in hepatic failure and death. A common cause for liver-
related death among persons with chronic hepatitis C is hepatocellular carcinoma (HCC),
occurring predominantly in those with cirrhosis 3–5, but reports have appeared of HCC
occurring, although far less commonly, in persons with bridging fibrosis without definite
cirrhosis 6–10. In studies from Asia, the annual incidence of HCC in subjects with hepatitis
C-related cirrhosis is reported to be 4–10%, whereas in European studies, the reported
annual incidence is 0.5–5% in comparable subjects 11–13. Data on the incidence of HCC in
subjects with advanced hepatitis C followed prospectively in the United States (U.S.) are
limited. Furthermore, the factors that predict a high likelihood of future HCC in such
subjects are not clearly defined.
Data from several previous studies, mostly from Japan, suggested that long-term treatment
with interferon-based regimens slowed progression of fibrosis and reduced the occurrence of
HCC in persons with chronic HCV infection 14–17. To determine whether these results apply
also in the U.S., we undertook the Hepatitis C Antiviral Long-Term Treatment against
Cirrhosis (HALT-C) Trial. A total of 1,050 persons with chronic hepatitis C and advanced
fibrosis or cirrhosis who were previous nonresponders to antiviral therapy were randomized
to receive either a reduced dose of peginterferon or no treatment for 3.5 years 18. Because
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HCC was one of the planned trial outcomes, the HALT-C trial provided an opportunity to
determine in a prospective controlled manner whether long-term peginterferon treatment
reduced the incidence of HCC and to identify risk factors associated with the development
of HCC in a U.S. cohort with chronic hepatitis C and advanced fibrosis or cirrhosis.
PATIENTS AND METHODS
The design of the HALT-C Trial has been described previously 18, 19. Briefly, patients with
detectable HCV RNA at 10 clinical centers had to meet the following criteria for enrollment:
failure to have achieved a sustained virologic response (SVR) after previous interferon
treatment with or without ribavirin, the presence of advanced hepatic fibrosis on liver biopsy
(Ishak fibrosis score ≥3), no history of hepatic decompensation or HCC, and the absence of
defined exclusion criteria (e.g., liver disease other than hepatitis C, uncontrolled medical or
psychiatric conditions, or contraindications to use of interferon or ribavirin).
Patients were treated with pegylated interferon alfa-2a (180 μg weekly) and ribavirin (1–1.2
g daily) for at least 24 weeks (“Lead-in” phase). Patients who had detectable serum HCV
RNA at treatment week 20 (protocol definition of nonresponse) were randomized at week 24
to maintenance therapy (pegylated interferon alfa-2a 90 μg weekly) or to no treatment for
the next 3.5 years. Patients with undetectable serum HCV RNA at week 20 were considered
responders and continued combination therapy for a total of 48 weeks. Patients in the
responder group in whom HCV RNA became detectable later during treatment
(breakthrough) or after stopping treatment (relapse) were offered enrollment into the
randomized trial. After approval of pegylated interferons, the protocol was amended to
allow randomization of patients who had failed treatment with pegylated interferon and
ribavirin outside this trial (Express patients). Following completion of the 3.5 years of the
randomized trial, all patients were invited to continue follow-up without treatment.
All patients were required to have an ultrasound, computed tomography (CT) or magnetic
resonance imaging (MRI) with no evidence of hepatic mass lesions suspicious for HCC.
Subjects enrolled in the Lead-in phase were required to have serum alpha-fetoprotein (AFP)
<200 ng/mL, while those enrolled as Express patients had to have AFP <1,000 ng/mL at the
screening visit. Of the 237 Express patients enrolled, only three had AFP >200 ng/mL at
entry and the highest AFP value was 315 ng/mL.
All patients had a liver biopsy performed prior to enrollment. For Lead-in patients, the
baseline liver biopsy was done at least 2 months following the last course of interferon
therapy and within 12 months prior to enrollment. For Express patients, a liver biopsy must
have been performed within 18 months prior to randomization, or a baseline liver biopsy
must have been performed at least 8 weeks after the end of the prior course of peginterferon
and ribavirin and within 24 weeks prior to randomization. Liver biopsies were repeated 1.5
and 3.5 years after randomization. All biopsies were reviewed in conference by a panel of 12
hepatic pathologists, who used the Ishak scoring system to grade inflammation (0–18) and to
stage fibrosis (0–6) 20. Liver biopsies performed for the diagnosis of HCC and explant livers
of patients who underwent liver transplantation for HCC were also submitted for review by
the group of hepatic pathologists.
HCC Surveillance and Diagnostic Criteria
Patients were seen every 3 months during the 3.5 years of the randomized trial and every 6
months thereafter. Patients who stopped treatment continued to be followed in the study
unless consent was withdrawn or a liver transplantation had occurred. A complete blood
count, a liver panel, and AFP level were obtained at the local clinical center at each visit.
Des-gamma-carboxy prothrombin (DCP) levels at enrollment were tested in batches with an
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enzyme immunoassay (Eisai Company, Tokyo, Japan) in a central laboratory at the
University of Michigan; the results were not reported to the investigators at the clinical sites.
Lead-in patients underwent an ultrasound examination of the liver 20 weeks and 12 months
after enrollment and then every 6–12 months. Express patients underwent ultrasound
examinations 6 months after enrollment and then every 6–12 months. Patients with an
elevated or rising AFP and those with new lesions on ultrasound were evaluated further with
a CT or MRI. Diagnostic liver biopsy and HCC treatment were conducted at the discretion
of investigators at each site. All patients underwent an endoscopy at the time of
randomization and after 3.5 years (i.e., at the end of the randomized trial). For the current
analysis, patients were categorized as not having varices (absent) or as having varices,
regardless of their size.
Two definitions of HCC were adopted, one for “definite” HCC and one for “presumed”
HCC. Definite HCC was defined by histologic confirmation or a new mass lesion on
imaging with AFP levels increasing to >1,000 ng/mL. Presumed HCC was defined as a new
mass lesion on ultrasound in the absence of histology and AFP was <1,000 ng/mL in
conjunction with one of the following characteristics: a) 2 liver imaging studies showing a
mass lesion with characteristics of HCC (vascular enhancement, wash out), b) progressively
enlarging lesion on ultrasound leading to death, or c) 1 additional imaging study showing a
mass lesion with characteristics of HCC that either increased in size over time or was
accompanied by increasing AFP levels. Tumors were staged based on the modified United
Network of Organ Sharing (UNOS) TNM system 21. Early HCC was defined as tumor stage
T1 (single lesion <2 cm in diameter) or T2 (single lesion between 2 and 5 cm or no more
than 3 lesions each <3 cm in diameter).
All cases of HCC (presumed and definite) were reviewed by an Outcomes Review Panel
comprised of rotating panels of three investigators. The outcomes review panel did not
include any radiologist and radiographic studies were not reviewed. However, the outcome
panel did review serial radiology reports from each HCC case to ascertain that the
predefined criteria were met, the date when these criteria were first met, and the tumor
staging. In cases where the outcomes review panel was unable to determine if the patient
had met criteria for HCC, the investigators were requested to provide additional information
including follow-up imaging or histology, and the case re-reviewed. All patients who met
criteria for presumed or definite HCC continued to be followed, and results of subsequent
imaging or histology (including liver explant and surgically resected specimen) were
submitted for review. An earlier report on all trial outcomes (clinical and histological)
included randomized patients with definite HCC (incident and prevalent) identified during
the first 3.5 years after randomization (up to April 30, 2007) 19. The current analysis
includes all randomized patients in the HALT-C Trial who had a diagnosis of definite or
presumed HCC as judged by the Outcomes Review Panel prior to October 15, 2007.
Statistical Analyses
Statistical analyses were performed at the Data Coordinating Center with SAS release 9.1
(SAS Institute, Cary, NC). Cumulative incidence of HCC was determined by Kaplan Meier
analysis and differences compared with the log rank test. Relation of baseline factors to risk
of HCC was assessed by t-test, chi-square test, or univariate Cox proportional hazards
regression. Several multivariate Cox proportional hazards models to estimate the risk of
HCC were tested. Variables with a p value <0.1 on univariate analysis and variables
reported previously to be associated with HCC (e.g., gender, race/ethnicity, the presence of
cirrhosis, alcohol consumption, and smoking) were entered into a multivariate analysis
(model I). Treatment assignment was also included, because the primary goal of the HALT-
C Trial was to determine if maintenance therapy with peginterferon would prevent clinical
outcomes, including HCC, in patients with chronic hepatitis C and advanced fibrosis or
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cirrhosis. Alternative multivariate analyses that included AFP and DCP separately and in
combination as well as aspartate aminotransferase (AST) and platelet count separately and
combined as AST-platelet ratio index (APRI) 22 were tested. Variables not readily available
in clinical practice were deleted from model I to create models with greater clinical utility
(models II, III and IV). The cohort was divided into three risk groups based on the resulting
individual estimates of model IV. The cumulative incidence of HCC among these groups
was determined by Kaplan Meier analysis and compared with the log rank test. A 2-sided
significance level of 5% was used for all analyses.
RESULTS
A total of 1,050 patients were randomized between January, 2001 and August, 2004. Forty-
five patients were excluded for the following reasons: a) prevalent HCC, defined as HCC
diagnosed within 12 months after enrollment (n=5); b) patients who had less than 12 months
follow-up after enrollment (n=38); and c) patients with a diagnosis of presumed HCC who
were followed for at least 24 months and did not show radiologic or clinical progression of
their liver masses (n=2). The characteristics of the remaining 1,005 patients included in this
analysis are shown in Table 1. The mean age of the patients was 50.2 years, 71% were men,
and 72% were Caucasian. Baseline biopsies showed bridging fibrosis (Ishak 3–4) in 59%
and cirrhosis (Ishak 5–6) in the remaining 41% of patients. The vast majority of the patients
(93%) had genotype 1 infection.
Incidence of HCC
During a median follow-up of 4.6 years after randomization (maximum of 6.7 years), 48
(4.8%) patients met criteria for HCC, 37 (77%) for definite HCC and 11 (23%) for presumed
HCC (Table 2). Thirty-four (71%) of the 48 patients with HCC were identified during the
randomized phase and the remaining 14 during the extended follow-up period. Thirty six
(75%) patients had early stage (T1/T2) HCC at the time of diagnosis. Twenty-six (54.2%)
patients were eligible for potentially curative treatment: 3 had surgical resection, 17
underwent liver transplantation and 6 had radiofrequency ablation +/− transarterial
chemoembolization (TACE). An additional 11 patients had TACE. Thus, in total 37 (77.1%)
patients had tumors diagnosed at an early enough stage that allowed them to receive
effective therapies.
Hepatocellular carcinoma developed in a similar proportion of peginterferon-treated
patients, 4.5% (23/495), and controls, 4.9% (25/510). The estimated annual incidence of
HCC was 1.1% in peginterferon-treated patients and 1.0% in controls. The cumulative
incidence of HCC 3 and 5 years after randomization was 1.9% and 5.4% for peginterferon-
treated patients and 1.9% and 5.0% for controls, respectively (p=0.78) (Figure 1A). The
incidence of HCC in the peginterferon-treated and control groups was similar regardless of
the inclusion or exclusion of cases of presumed HCC.
HCC was diagnosed in a higher percent of patients with cirrhosis, 6.1% (25/408), than in
those with bridging fibrosis, 3.9% (23/597). The estimated annual incidence of HCC was
0.8% among patients with bridging fibrosis and 1.4% among those with cirrhosis. The
cumulative incidence of HCC 3 and 5 years after randomization was 2.6% and 7.0% for
patients with cirrhosis and 1.4% and 4.1% for those with bridging fibrosis, respectively
(p=0.08) (Figure 1B).
HCC in patients without cirrhosis at enrollment
Of the 23 patients with HCC and an Ishak fibrosis score of 3 or 4 at enrollment, 13 advanced
to a score of 5–6, seven remained with a score of 3–4, and two had a score of 2 on
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subsequent biopsies, liver explants or surgically resected specimen; two patients did not
have repeat biopsies (Table 3). Thus, 17% (8/48) of the patients in whom HCC developed
did not have cirrhosis on at least two biopsies more than 2 years apart. HCC was diagnosed
after a median of 46.5 months (range 26–72) from enrollment in these eight patients. At
enrollment, six of these eight patients had platelet counts >150,000/mm3, and none had
esophageal varices; however, at the time of the diagnosis of HCC, only one patient had a
platelet count >150,000/mm3 (Table 4).
Risk factors for HCC
Baseline clinical and laboratory characteristics of the patients with and without HCC are
shown in Table 1. Based on univariate analysis, older age, lower BMI, lower white cell and
platelet counts, a lower albumin level, higher levels of alkaline phosphatase, AST, alanine
aminotransferase (ALT), AFP, and DCP, and the presence of esophageal varices were
significantly associated with HCC (each p<0.05). Black race, higher international
normalized ratio of prothrombin time (INR), and histological evidence of cirrhosis showed a
trend toward significance (p<0.1), while gender, diabetes, alcohol consumption, smoking,
treatment assignment, HCV genotype, and bilirubin were not significantly associated with
HCC.
Models to predict HCC incidence
Several Cox proportional hazards models were developed to predict the risk of HCC (Table
5). The initial model (Model I), which included significant variables from our univariate
analysis or from previously published analyses, was modified to eliminate variables that
were not significant on multivariate analysis. Three simplified models (Models II–IV) are
shown, because they include variables that are available in most patients with chronic
hepatitis C. The final model (Model IV) included age in years (continuous), black race
(black=1, non-black=0), alkaline phosphatase in U/L (continuous), the presence of
esophageal varices (present=1; absent=0), smoking (ever smoked=1, never smoked=0), and
platelet count × 1,000/mm3 (continuous). The regression formula for model IV is as follows:
age*0.049 + black race*0.712 + alkaline phosphatase*0.006 + esophageal varices *0.777 +
ever smoked*0.749 + platelets*−0.011. A score was calculated for each subject included in
this study, and cases were ranked in order of their calculated scores in this model. Three cut
points [0 to log10 (1.50), log 10 (1.50) to log10 (3.25), and >log10 (3.25)] were selected to
reflect low, intermediate, and high risk, as distinguished by 5-year cumulative incidence of
HCC of <1%, 1–5%, and >5%. The cumulative incidence of HCC 3 and 5 years after
randomization was 0% and 0.4% for patients in the low risk group; 1.5% and 4.2% for
patients in the intermediate risk group; and 6.1% and 17.8% for patients in the high risk
group, respectively (Figure 2).
Low platelet count and presence of esophageal varices were highly significant in the models
tested. The impact of esophageal varices and platelet count on the incidence of HCC is
shown in Figures 3A and 3B. The cumulative incidence of HCC 3 and 5 years after
randomization was 5.3% and 13.1%, 2.4% and 5.7%, and 0.6% and 2.6% for patients with
baseline platelet count <100, 100–149, and >150 × 1000/mm3, respectively. The estimated
annual incidence of HCC for patients in these three strata of platelet counts was 2.6%, 1.1%,
and 0.5%, respectively.
DISCUSSION
The major objective of the HALT-C Trial was to determine whether long-term treatment
with peginterferon would reduce progression of hepatitis C, including the development of
HCC. Support for the possibility that maintenance therapy might inhibit disease progression
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had come from a 2-year study of interferon maintenance therapy in a U.S. population 23.
Additionally, several early reports suggested that interferon therapy reduced the
development of HCC in Japanese and Italian patients with chronic hepatitis C 14–17.
Following initiation of the HALT-C Trial in 2000, numerous additional studies were
published that addressed the issue of antiviral treatment and development of HCC, leading
Craxi and Camma to perform a meta-analysis in 2005 of the then-existing studies 24. The
analysis included 20 trials, most of which were not randomized studies and 19 of which
showed (13 significantly) that antiviral therapy reduced the rate of development of HCC.
The validity of the meta-analysis, however, was limited by the marked heterogeneity among
the studies. The authors concluded that, although interferon treatment appeared to have a
beneficial impact on reducing the development of HCC, the effect was slight and was most
evident among the relatively few patients with cirrhosis who achieved an SVR. More recent
studies from Japan and Taiwan, however, have continued to support a positive impact of
antiviral therapy on the occurrence of HCC 25–28, but patients in these trials were not
randomized and, again, the benefit was observed mainly in patients who had achieved an
SVR.
In the present study, we found no significant difference in the incidence of HCC between
patients randomized to receive peginterferon maintenance therapy (23/495; 4.7%) and those
randomized to no treatment (25/510; 4.9%). The cumulative incidence of HCC 5 years after
randomization in the two cohorts was almost identical (treated: 5.4% and controls: 5.0%).
These data, collected prospectively from a large number of subjects followed closely for a
median of 4.6 years, suggest strongly that maintenance therapy with peginterferon, 90 μg/
week, does not reduce the incidence of HCC in patients with chronic hepatitis C and
advanced fibrosis or cirrhosis.
Because treatment had no effect on the rate of development of HCC in this trial, data from
the two cohorts (treated and untreated) could be combined to provide information on the
annual incidence of HCC among patients with advanced HCV-related liver disease in the
U.S. followed prospectively. Thus, for the combined cohort, the 3-year incidence of HCC
from study entry was 1.9%, increasing to 5.9% at 5 years, yielding an annual incidence of
HCC of 1.1%. This figure is consistent with, but at the lower range of, previous estimates of
the annual incidence of HCC both in the United States 29, now increasing 30, and in
Europe 3, 4, 12 but clearly lower than the rates reported among HCV-infected persons in
Japan 31–33.
The most likely explanation for the disparity between this trial and others in the efficacy of
interferon-based therapy in reducing the incidence of HCC is the difference in study design
between the HALT-C Trial and many of the previous studies. The HALT-C Trial was a
large, well powered, prospective, randomized, multicenter trial, with clear, predefined
criteria for the diagnosis of HCC. Many prior studies of interferon treatment were relatively
small, nonrandomized, and/or retrospective, with all the potential pitfalls of such
observations. Furthermore, in several previous reports, the decreased incidence of HCC was
observed mainly in patients who achieved an SVR, subjects who were excluded from the
HALT-C Trial. Potentially, the HALT-C Trial might have demonstrated efficacy of antiviral
therapy in preventing HCC had the maintenance treatment consisted of full-dose
peginterferon and ribavirin instead of half-dose peginterferon only. However, it is unlikely
that patients with advanced fibrosis or cirrhosis could tolerate full-dose combination therapy
for 3.5 years; only 59% of patients in the HALT-C Trial randomized to receive half-dose
peginterferon therapy were able to tolerate this lower dose for the entire 3.5 years. Finally,
the lower incidence of HCC observed in the HALT-C Trial compared to previous studies
could be related to differences in radiological and histological diagnostic criteria for HCC.
In the current study, cases of HCC identified within 12 months of enrollment were excluded
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as the tumors may have been present prior to entry into the trial. Although 23% (11/48) of
the HCC cases in our trial were categorized as presumed, rather than definite, HCC, almost
all of these cases fulfilled currently accepted diagnostic criteria for HCC 34–36. Indeed, the
diagnostic criteria utilized in this study were very stringent, and the outcome was the same
whether we included presumed cases or not.
The rate of HCC was higher in those whose baseline liver biopsy displayed cirrhosis than in
those with bridging fibrosis (6.1 percent versus 3.9 percent; p=0.08). While HCC has been
reported rarely in patients with chronic hepatitis C in the absence of cirrhosis, the high
frequency of HCC among subjects without cirrhosis in the present study was
unexpected 6–9, 37. One possible explanation is under-staging of the baseline liver biopsy
resulting from sampling error; however, eight of the 23 patients with HCC who had no
cirrhosis at enrollment also had no cirrhosis on follow-up liver biopsy (all 8 patients) or on
explant (1 patient). Alternatively, hepatic fibrosis may have progressed between the time of
the last study biopsy and the subsequent diagnosis of HCC as the interval between the last
biopsy with no cirrhosis and HCC diagnosis varied from 0–34 months (median 16).
Whatever the explanation for our observation, the development of HCC in persons with
noncirrhotic fibrosis raises the question of whether such patients should undergo HCC
surveillance, as is recommended for persons with established cirrhosis 33.
In seeking to identify features that might predict the future development of HCC, we
undertook an extensive analysis of baseline demographic characteristics, metabolic and viral
factors, laboratory values (including HCC biomarkers), disease severity, histologic findings,
markers of portal hypertension, treatment assignment, physical activity, and history of
alcohol use, smoking, and hormone use in women. On univariate analysis, treatment group
assignment was not associated with risk of HCC, and we could not confirm associations
reported by others between diabetes or alcohol use and the development of HCC 38–43. In
the current study, subjects with HCC had a lower BMI, not only at enrollment, but also,
based upon historical information, at ages 20 and 40, than subjects in whom HCC did not
develop. Prior reports of an association between obesity and HCC may have included
patients with non-alcoholic fatty liver disease 44–46. In this study, a strong association was
observed between the risk of HCC and a low platelet count, a high AST level, and the
presence of esophageal varices. This finding is consistent with an association in several
studies from Asia between a low platelet count and the development of HCC 47, 48 and an
association in a study from Italy between the presence of esophageal varices and HCC 49.
Numerous efforts have been made to develop predictive models for the development of
HCC in persons with advanced chronic liver disease 50–53. In multivariate analyses, these
investigators have identified varying factors, including age, gender, platelet count,
prothrombin time, albumin level, and AFP, as predictive variables. In the current study, we
found that gender, cirrhosis, and AFP were not significant in all models tested, while DCP
was. Smoking was not a significant factor on univariate analysis but was significant in
several regression models tested and showed a trend in our final model. Several simplified
models that included factors easily accessible in routine clinical settings were developed to
aid in predicting the risk of HCC among patients with hepatitis C and advanced fibrosis or
cirrhosis. These models may be useful for selecting high-risk patients with bridging fibrosis
and cirrhosis for HCC surveillance.
CONCLUSIONS
In the current analysis of hepatitis C patients with advanced fibrosis enrolled in the HALT-C
Trial, 3.5 years of maintenance therapy with peginterferon did not reduce the incidence of
HCC. The 1% annual incidence of HCC in this U.S. cohort was lower than those reported in
Lok et al. Page 8
Gastroenterology. Author manuscript; available in PMC 2013 August 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
studies of similar patients in Japan and Europe. Modeling based upon clinical and laboratory
features can identify patients at higher risk who might be candidates for more intense HCC
surveillance. Additional studies are required to confirm the occurrence of HCC among
patients with bridging fibrosis but no cirrhosis and to determine whether such patients
should undergo HCC surveillance.
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Figure 1.
Kaplan-Meier estimates of cumulative incidence of HCC (A) among patients randomized to
maintenance peginterferon treatment or control and (B) among patients with bridging
fibrosis (Ishak 3–4) vs. cirrhosis (Ishak 5–6) on baseline biopsy. Cases diagnosed within 12
months of enrollment were presumed to have been present at the time of enrollment and
were excluded. One patient in the treatment group met criteria for HCC 11 months after
randomization. This patient relapsed after 48 weeks of Lead-in treatment and had been in the
study for 16 months at the time of randomization.
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Figure 2.
Kaplan-Meier estimates of cumulative incidence of HCC among patients predicted to have
low, intermediate, and high risk of HCC according to regression Model IV.
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Figure 3.
Kaplan-Meier estimates of cumulative incidence of HCC (A) in patients with and without
esophageal varices or cirrhosis and (B) in patients with baseline platelet (plt) count <100,
100–149, and >150 × 1000/mm3
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